Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of TMX-049 in hyperuricemic patients with or without gout
jRCT2080223522Phase 2
- Sponsor
- Teijin Pharma
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TMX-049 in hyperuricemia and gout (3 arms), sponsored by Teijin Pharma.
02
Drugs
TMX-049
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on jRCT2080223522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223522.